论文部分内容阅读
本文作者Larry K Kv-ols等对25名在组织学上证明为转移性类癌瘤和类癌瘤综合征的病人经生长激素释放抑制素(somatostatin)长效类似物(SMS 201-995,山道土产品)治疗的作用进行了研究。药物是由病人自行皮下注射,每日3次,每次150μg。用药后,与类癌瘤综合征有关的面部潮红及腹泻在22名病人中迅速缓解。所有25名病人的24小时尿5-羟基吲哚乙酸(5-HIAA)排出量增高(24小时平均265mg,范围14～1079)。5-HIAA量增高为疾病活动的一个客观标志。与
The authors Larry K Kv-ols et al. 25 long-acting analogues of somatostatin on 25 histologically proven metastatic carcinoid tumors and carcinoid syndromes (SMS 201-995, Shan Dao) The effect of treatment of earth products) was studied. The drug is injected subcutaneously by the patient, three times a day, 150 μg each time. After treatment, facial flushing and diarrhea associated with carcinoid syndrome quickly resolved in 22 patients. The 24-hour urine 5-hydroxyindolacetic acid (5-HIAA) excretion increased in all 25 patients (average 265 mg, range 14 to 1079 at 24 hours). The increase in 5-HIAA levels is an objective marker of disease activity. versus